药品注册申请号:208418
申请类型:NDA (新药申请)
申请人:FRESENIUS KABI USA
申请人全名:FRESENIUS KABI USA LLC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 CALCIUM GLUCONATE CALCIUM GLUCONATE SOLUTION;INTRAVENOUS 1GM/10ML (100MG/ML) Yes Yes AP 2017/06/15 2017/06/15 Prescription
002 CALCIUM GLUCONATE CALCIUM GLUCONATE SOLUTION;INTRAVENOUS 5GM/50ML (100MG/ML) Yes Yes AP 2017/06/15 Prescription
003 CALCIUM GLUCONATE CALCIUM GLUCONATE SOLUTION;INTRAVENOUS 10GM/100ML (100MG/ML) Yes Yes AP 2017/06/15 Prescription
004 CALCIUM GLUCONATE IN SODIUM CHLORIDE CALCIUM GLUCONATE SOLUTION;INTRAVENOUS 1GM/50ML (20MG/ML) Yes Yes AP 2021/06/17 Prescription
005 CALCIUM GLUCONATE IN SODIUM CHLORIDE CALCIUM GLUCONATE SOLUTION;INTRAVENOUS 2GM/100ML (20MG/ML) Yes Yes AP 2021/06/17 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2022/10/17 SUPPL-13(补充) Approval Labeling STANDARD
2021/12/29 SUPPL-11(补充) Approval Labeling STANDARD
2021/06/17 SUPPL-7(补充) Approval Labeling STANDARD
2017/12/22 SUPPL-1(补充) Approval Labeling STANDARD
2017/06/15 ORIG-1(原始申请) Approval Type 7 - Drug Already Marketed without Approved NDA STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:CALCIUM GLUCONATE 剂型/给药途径:SOLUTION;INTRAVENOUS 规格:1GM/10ML (100MG/ML) 治疗等效代码:AP
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
208418 001 NDA CALCIUM GLUCONATE CALCIUM GLUCONATE SOLUTION;INTRAVENOUS 1GM/10ML (100MG/ML) Prescription Yes Yes AP 2017/06/15 FRESENIUS KABI USA
213071 001 ANDA CALCIUM GLUCONATE CALCIUM GLUCONATE SOLUTION;INTRAVENOUS 1GM/10ML (100MG/ML) Prescription No No AP 2022/10/14 NIVAGEN PHARMS INC
活性成分:CALCIUM GLUCONATE 剂型/给药途径:SOLUTION;INTRAVENOUS 规格:5GM/50ML (100MG/ML) 治疗等效代码:AP
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
208418 002 NDA CALCIUM GLUCONATE CALCIUM GLUCONATE SOLUTION;INTRAVENOUS 5GM/50ML (100MG/ML) Prescription Yes Yes AP 2017/06/15 FRESENIUS KABI USA
213071 002 ANDA CALCIUM GLUCONATE CALCIUM GLUCONATE SOLUTION;INTRAVENOUS 5GM/50ML (100MG/ML) Prescription No No AP 2023/10/19 NIVAGEN PHARMS INC
217689 001 ANDA CALCIUM GLUCONATE CALCIUM GLUCONATE SOLUTION;INTRAVENOUS 5GM/50ML (100MG/ML) Prescription No No AP 2023/10/19 SOMERSET
活性成分:CALCIUM GLUCONATE 剂型/给药途径:SOLUTION;INTRAVENOUS 规格:10GM/100ML (100MG/ML) 治疗等效代码:AP
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
208418 003 NDA CALCIUM GLUCONATE CALCIUM GLUCONATE SOLUTION;INTRAVENOUS 10GM/100ML (100MG/ML) Prescription Yes Yes AP 2017/06/15 FRESENIUS KABI USA
216541 001 ANDA CALCIUM GLUCONATE CALCIUM GLUCONATE SOLUTION;INTRAVENOUS 10GM/100ML (100MG/ML) Prescription No No AP 2023/08/21 B BRAUN MEDICAL INC
217689 002 ANDA CALCIUM GLUCONATE CALCIUM GLUCONATE SOLUTION;INTRAVENOUS 10GM/100ML (100MG/ML) Prescription No No AP 2023/10/19 SOMERSET
活性成分:CALCIUM GLUCONATE 剂型/给药途径:SOLUTION;INTRAVENOUS 规格:1GM/50ML (20MG/ML) 治疗等效代码:AP
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
208418 004 NDA CALCIUM GLUCONATE IN SODIUM CHLORIDE CALCIUM GLUCONATE SOLUTION;INTRAVENOUS 1GM/50ML (20MG/ML) Prescription Yes Yes AP 2021/06/17 FRESENIUS KABI USA
217174 001 ANDA CALCIUM GLUCONATE IN SODIUM CHLORIDE CALCIUM GLUCONATE SOLUTION;INTRAVENOUS 1GM/50ML (20MG/ML) Prescription No No AP 2023/09/05 AMNEAL
活性成分:CALCIUM GLUCONATE 剂型/给药途径:SOLUTION;INTRAVENOUS 规格:2GM/100ML (20MG/ML) 治疗等效代码:AP
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
208418 005 NDA CALCIUM GLUCONATE IN SODIUM CHLORIDE CALCIUM GLUCONATE SOLUTION;INTRAVENOUS 2GM/100ML (20MG/ML) Prescription Yes Yes AP 2021/06/17 FRESENIUS KABI USA
217174 002 ANDA CALCIUM GLUCONATE IN SODIUM CHLORIDE CALCIUM GLUCONATE SOLUTION;INTRAVENOUS 2GM/100ML (20MG/ML) Prescription No No AP 2023/09/05 AMNEAL
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database